Referencias bibliográficas

[1] Vantrimpont P Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, et al. Additive Beneficial Effects of Beta-Blockers to Angiotensin-Converting Enzyme Inhibitors in the Survival and Ventricular Enlar- gement (SAVE) Study. SAVE investigators. J Am Coll Cardiol. 1997; 29 (2):229-36.

[2] Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mor- tality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. 2008;52(22):1769-81.

[3] Kalogeropoulos A, Georgiopoulou V, Harris TB, Kritchevsky SB, Bauer DC, Smith AL, et al. Glycemic Status and Incident Heart Failure in Elderly Without History of Diabetes Mellitus: The Health, Aging, and Body Composition Study. 2009;15(7):593-9.

[4] Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Hulley SB, Grady D, et al. Predictors of Heart Failure Among Women With Coronary Disease. Circulation 2004;110 (11):1424-30.

[5] Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 2011;378 (9786):140- 6.

[6] Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996; 275(20):1557-62.

[7] Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 Expert Con- sensus Document on Hypertension in the Elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, Aerican Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 2011;57 (20):2037- 114.

[8] Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317 (7160):703-13.

[9] Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992;327 (10) :685-91.

[10] Lewis RV, McMurray J, McDevitt DG. Effects of Atenolol, Verapamil, and Xamoterol on Heart Rate and Exercise Tolerance in Digitalised Patients with Chronic Atrial Fibrillation. J Cardiovasc Phar- macol 1989; 13 (1):1-6.

[11] Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42 (11):1944-51. 

[12] Roy D, TaLajic M, NatteL S, Wyse DG, Dorian R Lee KL, et al. Rhythm Control versus Rate Control for AtriaL FibriLLation and Heart FaiLure. N EngL J Med 2008; 358 (25):2667-77.

[13] Effect of prophyLactic amiodarone on mortaLity after acute myocardiaL infarction and in con- gestive heart faiLure: meta-anaLysis of individual data from 6500 patients in randomised triaLs. Amiodarone TriaLs Meta-anaLysis Investigators. Lancet 1997; 350 (9089): 1417-24

[14] RiepoLi M, ViLLani GQ, Ronikowski R Wright A, FLather MD, Coats AJ. Overview and meta-anaLysis of randomised triaLs of amiodarone in chronic heart faiLure. Int J CardioL 1998; 66 (1):1-10.

[15] Guerci AD, GerstenbLith G, Brinker JA, Chandra NC, GottLieb SO, Bahr RD, et aL. A Randomized TriaL of Intravenous Tissue RLasminogen Activator for Acute MyocardiaL Infarction with Subsequent Randomization to ELective Coronary AngiopLasty. N EngL J Med 1987; 317 (26):1613-8.

[16]  KeeLey EC, Boura JA, Grines CL. Rrimary angiopLasty versus intravenous thromboLytic therapy for acute myocardiaL infarction: a quantitative review of 23 randomised triaLs. Lancet 2003; 361 (9351):13-20.

[17]  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992;327 (10) :685-91.

[18] Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ven- tricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357 (9266):1385-90.

[19] Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, K ber L, Maggioni AP, et al. Valsartan, Capto- pril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003; 349 (20):1893-906.

[20] Yusuf S, SLeight R Rogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting- enzyme inhibitor, ramipriL, on cardiovascuLar events in high-risk patients. The Heart Outcomes Rrevention EvaLuation Study Investigators. N EngL J Med. 2000; 342 (3):145-53.

[21] Efficacy of perindopriL in reduction of cardiovascuLar events among pa¬tients with stabLe coronary artery disease: randomised, doubLe-bLind, pLacebo-controLLed, muLti- centre triaL (the EURORA study). Lancet. 2003;362(9386):782-8.

[22] He FJ, MacGregor GA. Effect of Longer-term modest saLt reduction on bLood pressure. Cochrane Database Syst Rev. 2004; (3): CD004937

[23] Arcand J, Ivanov J, Sasson A, FLoras V, AL-Hesayen A, Azevedo ER, et aL. A high-sodium diet is asso- ciated with acute decompensated heart faiLure in ambuLatory heart faiLure patients: a prospecti- ve foLLow-up study. Am J CLin Nutr. 2011; 93(2):332-7.

[24] Good CB, MD, McDermott L, McCLoskey B,. Diet and Serum Rotassium in Ratients on ACE Inhibitors. JAMA 1995; 274 (7):538

[25] Riña IL, Apstein CS, BaLady GJ, BeLardineLLi R, Chaitman BR, Duscha BD, et aL. Exercise and Heart FaiLure: A Statement From the American Heart Association Committee on Exercise, RehabiLitation, and Rrevention. CircuLation 2003; 107 (8):1210-25.

[26] Davies EJ, Moxham T, Rees K, Singh S, Coats AJS, Ebrahim S, et al. Exercise training for systoLic heart faiLure: Cochrane systematic review and meta-anaLysis. Eur J Heart FaiL. 2010;12 (7):706-15.

[27]  O'Connor CM, WheLLan DJ, Lee KL, Keteyian SJ, Cooper LS, ELLis SJ, et aL. Efficacy and Safety of Exercise Training in Ratients With Chronic Heart FaiLure: HF-ACTION Randomized ControLLed TriaL. JAMA 2009; 301 (14):1439-50.

[28] Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, et al. Advanced chronicheart failure: A position statement from the Study Group on Advanced Heart Failure of the HeartFailure Association of the European Society of Cardiology. Eur J Heart Fail. 2007;9 (6-7): 684-94.

[29] Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, et al. INTERMACS Profiles ofAdvanced Heart Failure: The Current Picture. J Heart Lung Transplant.2009;28 (6):535–41.

[30] Morris CD, Carson S. Routine Vitamin Supplementation To Prevent Cardiovascular Disease: ASummary of the Evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;139(1):56–70.

[31] Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, et al. Testosterone supplementationin heart failure: a meta-analysis. Circ Heart Fail. 2012;5 (3):315–21.

[32-33] Crespo Leiro MG, Paniagua Martín MJ. Tratamiento de la insuficiencia cardíaca refractaria o avanzada.Revista Española de Cardiología. 2004; 57 (9):869–83

[34] Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on themorbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomizedcumulative survival (COPERNICUS) study. Circulation. 2002; 106 (17): 2194-9